{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-023989","form_type":"8-K","ticker":null,"cik":"0000859737","company_name":"HOLOGIC INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.158827+00:00","generated_at":"2026-06-03T01:19:50.214006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hologic beats Q2 guidance; raises FY2024 revenue & EPS outlook; acquires Endomagnetics for $310M","bullets":["Revenue $1,017.8M (-0.8% YoY); GAAP EPS $0.72, Non-GAAP EPS $1.03, both above guidance.","Organic revenue ex-COVID grew 4.9% constant currency; Diagnostics ex-COVID +9.8%, Surgical +7.7%.","Raised FY2024 revenue midpoint (constant currency) and EPS guidance on strong margins.","Agreed to acquire Endomagnetics Ltd for ~$310M to expand interventional breast business.","Operating cash flow $292.4M in Q2; cash flow from operations remains strong."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-023989","json":"https://secwatch.observer/filing/0001140361-24-023989.json","markdown":"https://secwatch.observer/filing/0001140361-24-023989.md","text":"https://secwatch.observer/filing/0001140361-24-023989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/859737/000114036124023989/0001140361-24-023989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/859737/000114036124023989/ef20028283_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:19:50.214006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf71f9ae336f91611310e9ea12a576eb455fabb2","claim":"HOLOGIC INC reported fiscal second quarter ended March 30, 2024 results: revenue $1,017.8 million, EPS GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03. Guidance raised.","evidence_excerpt":"Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/859737/000114036124023989/0001140361-24-023989-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 30, 2024"},{"label":"Revenue","value":"$1,017.8 million"},{"label":"EPS","value":"GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}